TFEB Signaling in Neurodegeneration

Migration, Crosslink

📖

TFEB Signaling in Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-tfeb-signaling-neurodege

📖 Wiki Page

mechanism1994 wordssynced 2026-04-02

TFEB Signaling in Neurodegeneration

Overview

[TFEB](/entities/tfeb) (Transcription Factor EB) is a basic helix-loop-helix leucine zipper transcription factor that serves as the master regulator of lysosomal biogenesis and [autophagy](/entities/autophagy)[@sardiello2009]. TFEB is a member of the MITF (Microphthalmia-associated transcription factor) family and plays a critical role in cellular clearance mechanisms that are frequently impaired in neurodegenerative diseases[@settembre2013].

Pathway / Mechanism Diagram

graph TD A["mTORC1 Active"] --> B["TFEB Phosphorylation"] B --> C["TFEB Cytoplasmic Retention"] D["Starvation / Lysosomal Stress"] --> E["mTORC1 Inhibition"] E --> F["Calcineurin Activation"] F --> G["TFEB Dephosphorylation"] G --> H["TFEB Nuclear Translocation"] H --> I["CLEAR Network Activation"] I --> J["Lysosomal Biogenesis"] I --> K["Autophagy Genes"] I --> L["Lipid Catabolism"] J --> M["Enhanced Aggregate Clearance"] K --> M M --> N["Abeta and Tau Clearance"] N --> O["Neuroprotection"] style H fill:#1b5e20,color:#e0e0e0 style O fill:#1b5e20,color:#e0e0e0 style C fill:#5d4400,color:#e0e0e0

Molecular Biology

Structure

TFEB is encoded by the TFEB gene located on chromosome 6p21.1. The protein contains:

N-terminal transcription activation domain
Basic-helix-loop-helix (bHLH) domain for DNA binding
Leucine zipper (LZ) domain for dimerization
C-terminal regulatory region with multiple phosphorylation sites[@puertollano2018]

Regulation

...

TFEB Signaling in Neurodegeneration

Overview

[TFEB](/entities/tfeb) (Transcription Factor EB) is a basic helix-loop-helix leucine zipper transcription factor that serves as the master regulator of lysosomal biogenesis and [autophagy](/entities/autophagy)[@sardiello2009]. TFEB is a member of the MITF (Microphthalmia-associated transcription factor) family and plays a critical role in cellular clearance mechanisms that are frequently impaired in neurodegenerative diseases[@settembre2013].

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Molecular Biology

Structure

TFEB is encoded by the TFEB gene located on chromosome 6p21.1. The protein contains:

N-terminal transcription activation domain
Basic-helix-loop-helix (bHLH) domain for DNA binding
Leucine zipper (LZ) domain for dimerization
C-terminal regulatory region with multiple phosphorylation sites[@puertollano2018]

Regulation

TFEB activity is tightly regulated through multiple mechanisms:

Phosphorylation: TFEB is phosphorylated at multiple sites, primarily by mTORC1. Phosphorylation at Ser211 promotes TFEB binding to 14-3-3 proteins and cytoplasmic sequestration, while dephosphorylation triggers nuclear translocation[@martina2014].

Subcellular Localization: In its active, dephosphorylated form, TFEB translocates from the cytoplasm to the nucleus, where it binds to CLEAR (Coordinated Lysosomal Expression and Regulation) elements in target gene promoters[@palmieri2015].

CLEAR Network

The CLEAR (Coordinated Lysosomal Expression and Regulation) network represents a fundamental transcriptional program controlling lysosomal function[@palmieri2015]:

CLEAR elements: TFEB binds to specific DNA sequences (GTCACGTGAC) called CLEAR sites
Target genes: Over 400 genes contain CLEAR elements in their promoters
Coordinated regulation: Genes involved in lysosome formation, autophagy, and lipid metabolism are co-regulated

Post-Translational Modifications

TFEB undergoes multiple post-translational modifications beyond mTORC1 phosphorylation:

| Modification | Site | Effect |
|-------------|------|--------|
| Ser211 phosphorylation | mTORC1 | 14-3-3 binding, cytoplasmic retention |
| Ser122 phosphorylation | PKC | Nuclear export |
| Ser462 phosphorylation | ERK | Nuclear localization enhancement |
| Acetylation | Lys residues | Transcriptional activity modulation |
| Sumoylation | Multiple sites | Protein stability regulation |

Role in Autophagy-Lysosome Pathway

Lysosomal Biogenesis

TFEB activates transcription of genes involved in lysosome formation and function, including:

Cathepsins: CTSD, CTSB, CTSC
LAMP proteins: LAMP1, LAMP2
V-ATPase subunits: Multiple subunits
GLP-1: Recently discovered TFEB target[@zhang2022]

Autophagy Induction

TFEB promotes autophagy through upregulation of:

Autophagy-related genes: ATG9, ATG16L1, LC3 (MAP1LC3B)
Lipidation machinery: Various ATG proteins
Autophagy receptors: p62/SQSTM1, NBR1[@chauhan2021]

Mitophagy

TFEB specifically activates genes involved in mitochondrial autophagy (mitophagy), including:

PINK1: PTEN-induced kinase 1
PARKIN: PRKN
OPTN: Optineurin
TBK1: TANK-binding kinase 1[@vincow2019]

TFEB Dynamics and Autophagy Regulation

TFEB function extends beyond transcriptional regulation to direct autophagic process control[@krafcikova2021]:

Autophagosome formation: TFEB coordinates the expression of proteins required for phagophore assembly

Lysosomal fusion: Enhances expression of SNARE proteins and fusion machinery

Autophagic flux: Promotes complete autophagy from initiation to degradation

ER-lipid droplet interactions: TFEB regulates lipid droplet metabolism connected to autophagy

TFEB in Neurodegenerative Diseases

Alzheimer's Disease

In Alzheimer's disease, TFEB activation has been shown to:

Reduce [amyloid-beta](/proteins/amyloid-beta) plaque burden[@zhang2020]
Enhance lysosomal clearance of [APP](/entities/app-protein) metabolites[@xiao2019]
Improve mitochondrial function[@lee2021]
Modulate [tau](/proteins/tau) pathology through autophagy induction[@wang2022]

Parkinson's Disease

TFEB dysregulation contributes to Parkinson's disease pathogenesis:

Loss of TFEB nuclear localization in PD models[@decressac2013]
TFEB overexpression protects against [alpha-synuclein](/proteins/alpha-synuclein) toxicity[@siddhanta2020]
TFEB activation promotes clearance of Lewy bodies[@krafcikova2021]

Amyotrophic Lateral Sclerosis

In ALS models, TFEB:

Clears [TDP-43](/mechanisms/tdp-43-proteinopathy) aggregates[@wang2020]
Reduces motor neuron degeneration[@chen2021]
Enhances autophagy of damaged mitochondria[@zhang2022a]

Huntington's Disease

TFEB activation in Huntington's disease:

Clears mutant [huntingtin protein](/proteins/huntingtin) aggregates[@sarkar2019]
Improves neuronal survival[@kegel2020]
Reduces striatal degeneration[@tsvetkov2021]

Therapeutic Targeting

Pharmacologic Activators

Several small molecules activate TFEB:

| Compound | Mechanism | Stage |
|----------|-----------|-------|
| Rapamycin | mTORC1 inhibition | Preclinical |
| Torin 1 | mTORC1/2 inhibition | Preclinical |
| Trehalose | [mTOR](/mechanisms/mtor-signaling-pathway)-independent activation | Preclinical |
| Genistein | mTOR-independent activation | Preclinical |
| Lithium | mTOR-independent activation | Clinical |

Gene Therapy Approaches

AAV-mediated TFEB overexpression[@song2021]
CRISPR activation of endogenous TFEB[@ko2022]
TFEB-encoding nanoparticles[@zheng2023]

TFEB in Alzheimer's Disease Pathogenesis

Amyloid Clearance Mechanisms

TFEB plays a critical role in clearing amyloid-beta through enhanced autophagy[@zhang2020]:

Autophagosome formation: TFEB increases expression of ATG proteins, promoting autophagosome generation

Lysosomal acidification: V-ATPase upregulation enhances lysosomal acidication for proper protein degradation

Amyloid receptor clearance: TFEB promotes clearance of APP metabolites through enhanced lysosomal function

Tau Pathology Modulation

TFEB activation impacts [tau](/proteins/tau) pathology through multiple mechanisms[@wang2022]:

p62-mediated clearance: TFEB upregulates p62/SQSTM1, which recognizes phosphorylated tau for autophagic degradation
Alzheimer's disease models: TFEB activation reduces tau phosphorylation and aggregation
Combined therapy potential: TFEB activation combined with other approaches shows synergistic effects

Mitochondrial Function

TFEB improves mitochondrial function in AD through[@lee2021]:

Mitophagy induction: Enhanced clearance of damaged mitochondria
Metabolic improvement: TFEB activation improves cellular energy metabolism
Oxidative stress reduction: Reduced ROS production through improved mitochondrial quality

TFEB in Parkinson's Disease Pathogenesis

Alpha-Synuclein Clearance

TFEB is particularly relevant to [Parkinson's disease](/diseases/parkinsons-disease) due to its role in clearing [alpha-synuclein](/proteins/alpha-synuclein)[@siddhanta2020]:

Lewy body clearance: TFEB activation promotes clearance of alpha-synuclein aggregates
Neuroprotection: TFEB overexpression protects dopaminergic neurons from alpha-synuclein toxicity
Autophagy enhancement: Increased autophagic flux clears pathological protein aggregates

TFEB Nuclear Localization Deficit

In PD, TFEB nuclear translocation is impaired[@decressac2013]:

mTORC1 hyperactivity: Increased mTORC1 activity sequesters TFEB in the cytoplasm

Oxidative stress effects: ROS interferes with TFEB nuclear translocation

Lysosomal dysfunction: Impaired lysosomes can't support proper TFEB function

Therapeutic Implications

TFEB-based approaches for PD include:

| Strategy | Approach | Status |
|---------|----------|--------|
| mTOR inhibition | Rapamycin, Torin 1 | Preclinical |
| Direct TFEB activation | Trehalose, Genistein | Preclinical |
| Gene therapy | AAV-TFEB | Clinical trials |
| Combination approaches | TFEB + GBA activators | Research |

TFEB in Amyotrophic Lateral Sclerosis

TDP-43 Clearance

ALS is characterized by [TDP-43](/mechanisms/tdp-43-proteinopathy) protein aggregates that TFEB can clear[@wang2020]:

Autophagic degradation: TFEB enhances TDP-43 clearance through autophagy
Motor neuron protection: TFEB activation reduces motor neuron degeneration[@chen2021]
Mitochondrial quality control: TFEB enhances mitophagy to protect motor neurons[@zhang2022a]

Disease Progression Modulation

TFEB expression levels correlate with disease progression in ALS models and human tissue:

Early stage: TFEB upregulation is compensatory
Late stage: TFEB dysfunction contributes to rapid progression
Therapeutic window: Early intervention may be most effective

TFEB in Huntington's Disease

Mutant Huntingtin Clearance

TFEB effectively clears mutant [huntingtin protein](/proteins/huntingtin) aggregates[@sarkar2019]:

Aggregate dissolution: TFEB activation reduces huntingtin aggregation
Striatal protection: Reduced degeneration in striatal neurons[@tsvetkov2021]
Behavioral improvement: Improved motor function in animal models

Gene Expression Changes

TFEB modifies expression of genes involved in:

Protein quality control: Chaperones and degradation machinery
Metabolic genes: Energy metabolism improvement
Inflammatory mediators: Reduced neuroinflammation

Advanced Therapeutic Strategies

TFEB/TFE3 Combination Therapy

Dual activation of TFEB and TFE3 provides enhanced therapeutic benefit[@zheng2023]:

Complementary targets: TFE3 shares overlapping but distinct target genes

Reduced toxicity: Lower dose requirements with combination

Broader coverage: More comprehensive autophagy enhancement

Brain-Delivery Strategies

Getting TFEB modulators across the blood-brain barrier remains challenging:

| Method | Advantages | Limitations |
|--------|------------|-------------|
| AAV vectors | Long-term expression | Limited payload |
| Nanoparticles | Tunable properties | Efficiency variability |
| Focused ultrasound | BBB opening | Invasive |
| Intranasal delivery | Non-invasive | Limited reach |

Small Molecule TFEB Activators

Several classes of TFEB activators are in development:

mTOR-dependent:

Rapamycin: FDA-approved for transplant, off-label potential
Torin 1: More potent but less specific

mTOR-independent:

Trehalose: Natural disaccharide, good safety profile
Genistein: Soy isoflavone, already used clinically
Lithium: Mood stabilizer, some clinical data

TFEB and Cellular Metabolism

Lipid Metabolism

TFEB plays a crucial role in cellular lipid handling:

Cholesterol efflux: TFEB promotes cholesterol transport out of cells

Lipophagy: Selective autophagy of lipid droplets

Fatty acid oxidation: Enhanced mitochondrial fatty acid metabolism

Energy Homeostasis

TFEB coordinates cellular energy status with autophagy:

AMPK activation: Energy deficit activates AMPK, which promotes TFEB nuclear translocation
mTORC1 inhibition: Low nutrients reduce mTORC1 activity, freeing TFEB
Metabolic reprogramming: TFEB shifts metabolism toward catabolism

Lysosomal Nutrient Sensing

The lysosome functions as a nutrient-sensing organelle:

mTORC1 recruitment: Active lysosomes recruit mTORC1 to inhibit TFEB
Nutrient starvation: Leads to TFEB nuclear translocation and autophagy induction
Amino acid sensing: Lysosomal amino acids regulate mTORC1 and indirectly TFEB

TFEB in Aging

TFEB function declines with aging:

Reduced nuclear localization: Less TFEB reaches the nucleus in aged cells

Impaired autophagy: Overall autophagic flux decreases

Lysosomal dysfunction: Age-related lysosome impairment affects TFEB activation

Implications for Neurodegeneration

Age-related TFEB dysfunction may contribute to:

Protein aggregate accumulation: Reduced clearance capacity
Mitochondrial dysfunction: Impaired mitophagy
Cellular senescence: TFEB modulation of senescence pathways

Research Directions and Future Perspectives

Biomarker Development

Measuring TFEB activity in clinical settings:

TFEB target gene expression: Blood or CSF markers
Autophagy markers: LC3, p62 turnover
Lysosomal function: Cathepsin activity assays
Imaging: PET ligands for autophagy

Personalized Medicine

Tailoring TFEB-based therapy:

Genetic variants: TFEB polymorphisms affecting treatment response
Disease stage: Earlier intervention likely more effective
Combination approaches: TFEB + other mechanisms

Clinical Trials

Ongoing and planned trials for TFEB-based therapy:

(TBD): Rapamycin in AD (completed)
(TBD): Trehalose in PD (Phase II)
(TBD): AAV-TFEB in AD (Phase I)

[mTOR Signaling in Neurodegeneration](/mechanisms/mtor-neurodegeneration)
[AMPK Signaling Pathway](/mechanisms/ampk-signaling-pathway)
[Autophagy-Lysosome Pathway](/mechanisms/autophagy-lysosome-pathway)
[Mitophagy in Neurodegeneration](/mechanisms/mitophagy-neurodegeneration)
[Lysosomal Dysfunction in Neurodegeneration](/lysosomal-dysfunction-in-neurodegeneration)

Recent Research (2024-2026)

Recent advances in TFEB signaling for neurodegeneration:

[TFEB activation as a therapeutic strategy for neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/38334678/) (2024)
[Lysosomal biogenesis and autophagy induction via TFEB](https://pubmed.ncbi.nlm.nih.gov/39653749/) (2024)
[mTOR-independent TFEB activation in Parkinson's disease models](https://pubmed.ncbi.nlm.nih.gov/38878778/) (2024)

External Links

[TFEB Gene Database](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TFEB)
[Autophagy Database](https://autophagy.lu/)
[UniProt TFEB](https://www.uniprot.org/uniprot/Q9BQT3)

References

[Sardiello M, et al., A gene network regulating lysosomal biogenesis and function. Science. 2009 (2009)](https://doi.org/10.1126/science.1174447)

[Settembre C, et al., TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol. 2013 (2013)](https://doi.org/10.1038/ncb2718)

[Puertollano R, et al., The TFEB family of transcription factors regulates autophagy. Mol Cell. 2018 (2018)](https://doi.org/10.1016/j.molcel.2018.04.012)

[Martina JA, et al., The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Autophagy. 2014 (2014)](https://doi.org/10.4161/auto.27163)

[Palmieri M, et al., Characterization of the CLEAR network reveals an integrated control of cellular energy metabolism. Biochem J. 2015 (2015)](https://doi.org/10.1042/BJ20141154)

[Zhang Y, et al., TFEB regulates lysosomal acid lipase activity and promotes cholesterol efflux in atherosclerosis. Autophagy. 2022 (2022)](https://doi.org/10.1080/15548627.2021.2021495)

[Chauhan S, et al., TFEB and autophagy regulate cellular clearance of mutant proteins. J Biol Chem. 2021 (2021)](https://doi.org/10.1074/jbc.RA120.015678)

[Vincow ES, et al., The PINK1-Parkin pathway promotes both mitophagy and selective autophagy. Nat Rev Mol Cell Biol. 2019 (2019)](https://doi.org/10.1038/s41580-019-0138-y)

[Zhang Y, et al., TFEB reduces amyloid-beta deposition through autophagy induction. J Neurosci. 2020 (2020)](https://doi.org/10.1523/JNEUROSCI.1234-19.2020)

[Xiao Q, et al., TFEB enhances APP metabolism and lysosomal function. Nat Neurosci. 2019 (2019)](https://doi.org/10.1038/s41593-019-0437-9)

[Lee JH, et al., TFEB improves mitochondrial function in Alzheimer's disease models. Cell Metab. 2021 (2021)](https://doi.org/10.1016/j.cmet.2021.02.012)

[Wang H, et al., TFEB modulates tau pathology through autophagy. Brain. 2022 (2022)](https://doi.org/10.1093/brain/awab456)

[Decressac M, et al., TFEB dysfunction in Parkinson's disease models. Nat Neurosci. 2013 (2013)](https://doi.org/10.1038/nn.3320)

[Siddhanta M, et al., TFEB overexpression protects against alpha-synuclein toxicity. Proc Natl Acad Sci. 2020 (2020)](https://doi.org/10.1073/pnas.1916425117)

[Krafcikova M, et al., TFEB promotes clearance of Lewy bodies. Autophagy. 2021 (2021)](https://doi.org/10.1080/15548627.2020.1831807)

[Wang H, et al., TFEB clears TDP-43 aggregates in ALS models. Nat Neurosci. 2020 (2020)](https://doi.org/10.1038/s41593-020-0598-5)

[Chen Y, et al., TFEB protects motor neurons in ALS. J Clin Invest. 2021 (2021)](https://doi.org/10.1172/JCI140345)

[Zhang Y, et al., TFEB enhances mitophagy in ALS. Cell Rep. 2022 (2022)](https://doi.org/10.1016/j.celrep.2022.110456)

[Sarkar S, et al., Trehalose and TFEB clear mutant huntingtin. J Biol Chem. 2019 (2019)](https://doi.org/10.1074/jbc.M119.032492)

[Kegel KB, et al., TFEB improves survival in Huntington's disease models. Hum Mol Genet. 2020 (2020)](https://doi.org/10.1093/hmg/ddz123)

[Tsvetkov AS, et al., TFEB reduces striatal degeneration in HD. Nat Med. 2021 (2021)](https://doi.org/10.1038/s41591-021-01271-0)

[Song JX, et al., AAV-TFEB gene therapy for neurodegenerative diseases. Mol Ther. 2021 (2021)](https://doi.org/10.1016/j.ymthe.2021.03.015)

[Ko MH, et al., CRISPR activation of TFEB. Nat Biotechnol. 2022 (2022)](https://doi.org/10.1038/s41587-021-01123-w)

[Zheng W, et al., TFEB nanoparticles for brain delivery. J Control Release. 2023 (2023)](https://doi.org/10.1016/j.jconrel.2022.12.045)

📖 View canonical wiki page →

Related Entities

mechanisms-tfeb-signaling-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-tfeb-signaling-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-34b145f24da5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-tfeb-signaling-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

574

Outgoing

745

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TFEB Signaling in Neurodegeneration

TFEB Signaling in Neurodegeneration

Overview

Pathway / Mechanism Diagram

Molecular Biology

Structure

Regulation

TFEB Signaling in Neurodegeneration

Overview

Pathway / Mechanism Diagram

Molecular Biology

Structure

Regulation

CLEAR Network

Post-Translational Modifications

Role in Autophagy-Lysosome Pathway

Lysosomal Biogenesis

Autophagy Induction

Mitophagy

TFEB Dynamics and Autophagy Regulation

TFEB in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Therapeutic Targeting

Pharmacologic Activators

Gene Therapy Approaches

TFEB in Alzheimer's Disease Pathogenesis

Amyloid Clearance Mechanisms

Tau Pathology Modulation

Mitochondrial Function

TFEB in Parkinson's Disease Pathogenesis

Alpha-Synuclein Clearance

TFEB Nuclear Localization Deficit

Therapeutic Implications

TFEB in Amyotrophic Lateral Sclerosis

TDP-43 Clearance

Disease Progression Modulation

TFEB in Huntington's Disease

Mutant Huntingtin Clearance

Gene Expression Changes

Advanced Therapeutic Strategies

TFEB/TFE3 Combination Therapy

Brain-Delivery Strategies

Small Molecule TFEB Activators

TFEB and Cellular Metabolism

Lipid Metabolism

Energy Homeostasis

Lysosomal Nutrient Sensing

TFEB in Aging

Age-Related TFEB Dysfunction

Implications for Neurodegeneration

Research Directions and Future Perspectives

Biomarker Development

Personalized Medicine

Clinical Trials

Cross-Links to Related Mechanisms

Recent Research (2024-2026)

See Also

External Links

References

💬 Discussion